{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T01:39:29Z","timestamp":1768009169600,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03419-2","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T18:01:51Z","timestamp":1687284111000},"page":"42-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["To support the use of NT-proBNP to better detect heart failure in patients with type 2 diabetes"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-9128","authenticated-orcid":false,"given":"Francesco","family":"Lapi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ettore","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Medea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Parretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Cricelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,20]]},"reference":[{"key":"3419_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"A. Groenewegen, F.H. Rutten, A. Mosterd, A.W. Hoes, Epidemiology of heart failure. Eur. J. Heart Fail. 22, 1342\u20131356 (2020)","journal-title":"Eur. J. Heart Fail."},{"key":"3419_CR2","doi-asserted-by":"crossref","unstructured":"A. Ceriello, D. Catrinoiu, C. Chandramouli, F. Cosentino, A.C. Dombrowsky, B. Itzhak, N.M. Lalic, F. Prattichizzo, O. Schnell, P.M. Seferovi\u0107, P. Valensi, E. Standl, CVD EASD Study Group, Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc. Diabetol. 20, 218 (2021).","DOI":"10.1186\/s12933-021-01408-1"},{"key":"3419_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"P.M. Seferovi\u0107, M.C. Petrie, G.S. Filippatos, S.D. Anker, G. Rosano, J. Bauersachs, W.J. Paulus, M. Komajda, F. Cosentino, R.A. de Boer, D. Farmakis, W. Doehner, E. Lambrinou, Y. Lopatin, M.F. Piepoli, M.J. Theodorakis, H. Wiggers, J. Lekakis, A. Mebazaa, M.A. Mamas, C. Tsch\u00f6pe, A.W. Hoes, J.P. Seferovi\u0107, J. Logue, T. McDonagh, J.P. Riley, I. Milinkovi\u0107, M. Polovina, D.J. van Veldhuisen, M. Lainscak, A.P. Maggioni, F. Ruschitzka, J.J.V. McMurray, Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 20, 853\u2013872 (2018)","journal-title":"Eur. J. Heart Fail."},{"key":"3419_CR4","doi-asserted-by":"publisher","unstructured":"M. Kahn, A.D. Grayson, P.S. Chaggar, M.J. Ng Kam Chuen, A. Scott, C. Hughes, N.G. Campbell, Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction. Eur. Heart J. (2021). https:\/\/doi.org\/10.1093\/eurheartj\/ehab629","DOI":"10.1093\/eurheartj\/ehab629"},{"key":"3419_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ejheart.2008.07.014","volume":"10","author":"A Maisel","year":"2008","unstructured":"A. Maisel, C. Mueller, K. Adams, S.D. Anker, N. Aspromonte, J.G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, G.S. Filippatos, G.C. Fonarow, P. Jourdain, M. Komajda, P.P. Liu, T. McDonagh, K. McDonald, A. Mebazaa, M.S. Nieminen, W.F. Peacock, M. Tubaro, R. Valle, M. Vanderhyden, C.W. Yancy, F. Zannad, E. Braunwald, State of the art: Using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail. 10, 824\u2013839 (2008)","journal-title":"Eur. J. Heart Fail."},{"key":"3419_CR6","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.3399\/bjgp16X688393","volume":"67","author":"CJ Taylor","year":"2017","unstructured":"C.J. Taylor, A.K. Roalfe, R. Iles, F.D.R. Hobbs, P. Barton, M.R. Cowie, R.C. Davis, J. Deeks, J. Mant, D. McCahon, L. Tait, G. Sutton Primary care REFerral for EchocaRdiogram (REFER) in heart failure: A diagnostic accuracy study. Br. J. Gen. Pract. 67, e94\u2013e102 (2017)","journal-title":"Br. J. Gen. Pract."},{"key":"3419_CR7","doi-asserted-by":"crossref","unstructured":"E. Roberts, A.J. Ludman, K. Dworzynski, A. Al-Mohammad, M.R. Cowie, J.J.V. McMurray, J. Mant, The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 350 (2015)","DOI":"10.1136\/bmj.h910"},{"key":"3419_CR8","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/eurheartj\/ehq163","volume":"31","author":"P Hildebrandt","year":"2010","unstructured":"P. Hildebrandt, P.O. Collinson, R.N. Doughty, A. Fuat, D.C. Gaze, F. Gustafsson, J. Januzzi, J. Rosenberg, R. Senior, M. Richards Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. Eur. Heart J. 31, 1881\u20131889 (2010)","journal-title":"Eur. Heart J."},{"key":"3419_CR9","doi-asserted-by":"crossref","unstructured":"P. Hildebrandt, P.O. Collinson, Amino-terminal pro-b-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am. J. Cardiol. 101 (2008)","DOI":"10.1016\/j.amjcard.2007.11.016"},{"key":"3419_CR10","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1161\/01.CIR.0000054164.99881.00","volume":"107","author":"IS Anand","year":"2003","unstructured":"I.S. Anand, L.D. Fisher, Y.T. Chiang, R. Latini, S. Masson, A.P. Maggioni, R.D. Glazer, G. Tognoni, J.N. Cohn Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107, 1278\u20131283 (2003)","journal-title":"Circulation"},{"key":"3419_CR11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2337\/dc17-0509","volume":"40","author":"T Ohkuma","year":"2017","unstructured":"T. Ohkuma, M. Woodward, J. Chalmers, Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: The ADVANCE trial. Diabetes care 40, 1203\u20131209 (2017). Diabetes Care 41, e39 (2018)","journal-title":"Diabetes care"},{"key":"3419_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. B\u00f6hm, H.-P. Brunner\u2013La Rocca, D.-J. Choi, V. Chopra, E. Chuquiure-Valenzuela, N. Giannetti, J.E. Gomez-Mesa, S. Janssens, J.L. Januzzi, J.R. Gonzalez-Juanatey, B. Merkely, S.J. Nicholls, S.V. Perrone, I.L. Pi\u00f1a, P. Ponikowski, M. Senni, D. Sim, J. Spinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, J. Zhang, P. Carson, C.S.P. Lam, N. Marx, C. Zeller, N. Sattar, W. Jamal, S. Schnaidt, J.M. Schnee, M. Brueckmann, S.J. Pocock, F. Zannad, M. Packer Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med 385, 1451\u20131461 (2021)","journal-title":"N. Engl. J. Med"},{"key":"3419_CR13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"S.D. Solomon, J.J.V. McMurray, B. Claggett, R.A. de Boer, D. DeMets, A.F. Hernandez, S.E. Inzucchi, M.N. Kosiborod, C.S.P. Lam, F. Martinez, S.J. Shah, A.S. Desai, P.S. Jhund, J. Belohlavek, C.-E. Chiang, C.J.W. Borleffs, J. Comin-Colet, D. Dobreanu, J. Drozdz, J.C. Fang, M.A. Alcocer-Gamba, W. Al Habeeb, Y. Han, J.W. Cabrera Honorio, S.P. Janssens, T. Katova, M. Kitakaze, B. Merkely, E. O\u2019Meara, J.F.K. Saraiva, S.N. Tereshchenko, J. Thierer, M. Vaduganathan, O. Vardeny, S. Verma, V.N. Pham, U. Wilder\u00e4ng, N. Zaozerska, E. Bachus, D. Lindholm, M. Petersson, A.M. Langkilde Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022)","journal-title":"N. Engl. J. Med."},{"key":"3419_CR14","doi-asserted-by":"crossref","unstructured":"N. Okumura, P.S. Jhund, J. Gong, M.P. Lefkowitz, A.R. Rizkala, J.L. Rouleau, V.C. Shi, K. Swedberg, M.R. Zile, S.D. Solomon, M. Packer, J.J.V. Mcmurray. Effects of Sacubitril\/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. Circ. Heart Fail. 9 (2016)","DOI":"10.1161\/CIRCHEARTFAILURE.116.003212"},{"key":"3419_CR15","unstructured":"X Report Health Search. https:\/\/healthsearch.it\/report\/ (2017)"},{"key":"3419_CR16","unstructured":"M. TA, M. M, A. M, G. RS, B. A, B. M, B. H, B. J, \u010c. J, C. O, C. JGF, C. AJS, C.-L. MG, F. D, G. M, H. S, H. AW, J. T, J.EA, L. M, L. CSP, L. AR, M. JJV, M. A, M. R, M. C, F. P. M, P. S, R. GMC, R. F, K. S. A, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021)"},{"key":"3419_CR17","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00125-014-3375-9","volume":"57","author":"AH Price","year":"2014","unstructured":"A.H. Price, P. Welsh, C.J. Weir, I. Feinkohl, C.M. Robertson, J.R. Morling, S. McLachlan, M.W.J. Strachan, N. Sattar, J.F. Price N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: The Edinburgh type 2 diabetes study. Diabetologia 57, 2505\u20132512 (2014)","journal-title":"Diabetologia"},{"key":"3419_CR18","doi-asserted-by":"publisher","unstructured":"C. Piccinni, I.C. Antonazzo, M. Simonetti, M.G. Mennuni, D. Parretti, C. Cricelli, D. Colombo, M. Nica, I. Cricelli, F. Lapi, How many and who are patients with heart failure eligible to SGLT2 inhibitors? Responses from the combination of administrative healthcare and primary care databases. Int. J. Cardiol. (2022). https:\/\/doi.org\/10.1016\/J.IJCARD.2022.09.053","DOI":"10.1016\/J.IJCARD.2022.09.053"},{"key":"3419_CR19","doi-asserted-by":"crossref","unstructured":"C. Piccinni, L. Dondi, S. Calabria, G. Ronconi, A. Pedrini, F. Lapi, E. Marconi, D. Parretti, G. Medea, C. Cricelli, N. Martini, A. Pietro Maggioni, The Burden of Chronic Heart Failure in Primary Care in Italy. High Blood Press. Cardiovasc. Prev. 24 (2017)","DOI":"10.1007\/s40292-017-0193-4"},{"key":"3419_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/03007995.2022.2052513","volume":"38","author":"I Cricelli","year":"2022","unstructured":"I. Cricelli, E. Marconi, F. Lapi, Clinical Decision Support System (CDSS) in primary care: from pragmatic use to the best approach to assess their benefit\/risk profile in clinical practice. Curr. Med. Res. Opin. 38, 827\u2013829 (2022)","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03419-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03419-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03419-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:25:01Z","timestamp":1693211101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03419-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["3419"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03419-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,20]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.L. and E.M. provided consultancies in protocol preparation for epidemiological studies and data analyses for Roche Diagnostics, Astra Zeneca, Novartis, MSD. G.M., D.P. and C.C. provided clinical consultancies for Roche Diagnostics, Astra Zeneca, Novartis, MSD. A.P.M. received personal fees for the participation in clinical studies supported by Bayer, Novartis, Fresenius and Astra Zeneca, outside the present work. C.P. has no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Scientific Committee of the Italian College of General Practitioners and Primary Care. This study followed the principles of the Declaration of Helsinki, and it is compliant with the ENCePP (European Network of Centers for Pharmacoepidemiology and Pharmacovigilance) Guide on Methodological Standards in Pharmacoepidemiology. Furthermore, as this is a retrospective, non\u2010interventional, observational study, the data were fully anonymized. There is therefore no need for informed consent (Italian Drug Agency note dated 3rd of August 2007).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}